Zepbound vs Wegovy: Which Is Right for a Mother?

What the two brands actually are now

Zepbound (tirzepatide) and Wegovy (semaglutide) are the two brand-name products approved in the US for weight management. The same two molecules are sold under different brands for type 2 diabetes — Mounjaro is tirzepatide, Ozempic is semaglutide — which is where most of the confusion in this comparison comes from.

The bigger recent change is one most comparisons have not caught up with. Wegovy is no longer only an injection: an oral 25 mg once-daily semaglutide tablet was approved in December 2025 and now sits on the same label as the pen. Zepbound remains injection-only. For a mother choosing between the two brands rather than between the two molecules, that is the single most consequential difference on this page.

Those rows come from the two current prescribing informations, read in full^3,4.

What the head-to-head actually found

SURMOUNT-5 randomized 751 adults with obesity and without type 2 diabetes, 1:1, to the maximum tolerated dose of tirzepatide (10 or 15 mg) or semaglutide (1.7 or 2.4 mg) for 72 weeks. Mean weight change was −20.2% with tirzepatide against −13.7% with semaglutide; waist circumference fell 18.4 cm against 13.0 cm; and participants on tirzepatide were more likely to cross every reported threshold — 10%, 15%, 20% and 25% of body weight. Gastrointestinal effects were the most common adverse events in both groups, mostly mild to moderate, and occurred primarily during dose escalation rather than at a settled maintenance dose¹.

Two things about that trial belong in the same breath as the result. It was open-label, so every participant knew which product they were injecting, and it was funded by Zepbound's manufacturer. The gap is large enough to survive both objections, but "superior in a trial" is not "better for you". The wider molecule-level evidence — the pivotal placebo-controlled trials and the two withdrawal trials — is laid out on semaglutide vs tirzepatide.

The tablet changes the Wegovy question, but it is not the easy option

For a lot of mothers the binding constraint is not which product is stronger; it is which one is still being taken in eighteen months. So a daily tablet sounds like the obvious answer, and it is worth reading the conditions before assuming it.

Wegovy tablets are taken once daily on an empty stomach in the morning, swallowed whole, with no more than four ounces of water and nothing else to drink — then nothing to eat, drink, or take by mouth for at least 30 minutes afterwards⁴. In a house that wakes up at six with other people's needs attached, a protected thirty-minute window every single morning is a genuinely harder commitment than one injection on a Sunday night. Neither is obviously easier; they are different kinds of difficult, and the honest question is which kind fits your actual mornings.

There is also a line in the table above that has no equivalent for the pen. The tablet formulation contains SNAC, an absorption enhancer, and the label states that SNAC and its metabolites are present in human milk — so on tablets, breastfeeding is not recommended, while the injection, which contains no SNAC, is named on the label as the alternative⁴. If you are nursing, the two Wegovy forms are not interchangeable. Our guide to GLP-1s and breastfeeding goes through what each label permits in detail.

Cost, and what a manufacturer-funded model claims

List prices, savings-card terms and coverage rules on both brands move often enough that any number printed here would be stale before you read it. What does exist is a formal economic analysis built on the SURMOUNT-5 data, and it reached a stronger conclusion than "you pay more for the better one": modelled over a lifetime from a US societal perspective, tirzepatide was both less costly and more effective than semaglutide — $41,688 in per-patient savings and 0.506 additional quality-adjusted life years, with 70 fewer cases of type 2 diabetes and 10 fewer cardiovascular events projected per 1,000 patients treated².

Read that for what it is. It is a patient-level simulation, not observed spending; it was authored and funded by Eli Lilly, who make Zepbound; and a societal perspective counts things a household budget does not, including lost productivity. It says nothing at all about what your pharmacy will charge you next month. For most mothers the number that decides this is what your plan covers and what comes out of pocket after it — price both brands, and both Wegovy forms, before you settle on one. Outside the brand lane, telos rx is a tirzepatide-forward compounded platform worth noting for a different reason: its own comparison pages disagree on whether it offers semaglutide at all, which is exactly the kind of basic fact worth confirming directly before a mother who wants a specific molecule signs up anywhere. The same caution applies further down the compounded lane. MangoRx sells only an oral semaglutide tablet — no injectable, and no tirzepatide product at all. Pomegranate Health sold compounded tirzepatide as recently as an earlier check; as of an August 2026 visit its Weight Loss category lists only compounded semaglutide. Ivologist doesn't offer compounded tirzepatide either — only a request-based, unpriced path to branded Zepbound. If tirzepatide specifically is the plan, confirm the molecule is actually for sale today rather than trusting a historical listing.

The two label gaps a brand name hides

• Birth control. The Zepbound label tells patients using oral hormonal contraceptives to switch to a non-oral method or add a barrier method for four weeks after starting and four weeks after each dose increase³. The Wegovy prescribing information carries no contraception advice at all — the word does not appear in it⁴. If you rely on the pill, that gap is not a footnote, and it is the one thing on this page that could change a life rather than a number. Our guide to GLP-1s and birth control covers what to do about it.
• Pregnancy timing. These are not symmetrical either. Wegovy's label instructs patients to stop at least two months before a planned pregnancy, because of semaglutide's long half-life⁴. Zepbound's label sets no pre-pregnancy interval at all; it says to discontinue when a pregnancy is recognized³. If you are planning to conceive, ask specifically for a stop date rather than assuming one brand's rule applies to the other.

What is settled here, and what is not

The efficacy comparison is the strongest part of this page and the least useful for choosing. One adequately powered randomized trial, run to 72 weeks, says tirzepatide outperforms semaglutide on mean weight and waist reduction — a real finding about groups, from an open-label trial its maker paid for.

Everything else is weaker evidence carrying more weight in an actual decision. The label differences are documented facts rather than trial results, and the questions a mother is likeliest to be asking — how either brand behaves through a planned pause for a pregnancy, whether the tablet or the pen is easier to stay on for years, what happens to a nursing infant on the tablet formulation — have prescribing-information statements standing in for studies that have not been run. The economics rest on a sponsor's model, not on receipts. So bring the specifics a trial cannot know, which contraception you use, whether you are nursing, whether you are planning another pregnancy, what your plan covers, to a clinician, and let those decide it rather than the headline percentage.